BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36972359)

  • 1. Patient Characteristics Associated With Chemotherapy-Induced Peripheral Neuropathy Severity in a Phase II Clinical Trial: A Retrospective Analysis.
    Zhi WI; Dreyfus N; Lessing A; Galantino M; Piulson L; Kot KL; Li S; Bao T
    Oncologist; 2023 Jul; 28(7):604-608. PubMed ID: 36972359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
    Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
    JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
    Bao T; Seidman AD; Piulson L; Vertosick E; Chen X; Vickers AJ; Blinder VS; Zhi WI; Li Q; Vahdat LT; Dickler MN; Robson ME; Mao JJ
    Eur J Cancer; 2018 Sep; 101():12-19. PubMed ID: 30007894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.
    Nyrop KA; Deal AM; Reeder-Hayes KE; Shachar SS; Reeve BB; Basch E; Choi SK; Lee JT; Wood WA; Anders CK; Carey LA; Dees EC; Jolly TA; Kimmick GG; Karuturi MS; Reinbolt RE; Speca JC; Muss HB
    Cancer; 2019 Sep; 125(17):2945-2954. PubMed ID: 31090930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221.
    Chen CS; Zirpoli G; Barlow WE; Budd GT; McKiver B; Pusztai L; Hortobagyi GN; Albain KS; Damaj MI; Godwin AK; Thompson A; Henry NL; Ambrosone CB; Stringer KA; Hertz DL
    J Natl Compr Canc Netw; 2023 Nov; 21(11):1172-1180.e3. PubMed ID: 37935109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent weekly paclitaxel-induced peripheral neuropathy in early breast cancer patients enrolled in a randomized trial of cryotherapy.
    Shigematsu H; Kimura Y; Itagaki T; Yasui D
    Medicine (Baltimore); 2023 Apr; 102(16):e33580. PubMed ID: 37083796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer.
    Speck RM; Sammel MD; Farrar JT; Hennessy S; Mao JJ; Stineman MG; DeMichele A
    J Oncol Pract; 2013 Sep; 9(5):e234-40. PubMed ID: 23943894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population.
    Greenwald MK; Ruterbusch JJ; Beebe-Dimmer JL; Simon MS; Albrecht TL; Schwartz AG
    Cancer; 2019 Jan; 125(2):269-277. PubMed ID: 30387871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
    Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F
    JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial using surgical gloves to prevent chemotherapy-induced peripheral neuropathy by paclitaxel in breast cancer patients (AIUR trial).
    Kang YJ; Yoon CI; Yang YJ; Baek JM; Kim YS; Jeon YW; Rhu J; Yi JP; Kim D; Oh SJ
    BMC Cancer; 2023 Jun; 23(1):570. PubMed ID: 37340369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.
    Bao T; Basal C; Seluzicki C; Li SQ; Seidman AD; Mao JJ
    Breast Cancer Res Treat; 2016 Sep; 159(2):327-33. PubMed ID: 27510185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study.
    Salgado TM; Liu J; Reed HL; Quinn CS; Syverson JG; Le-Rademacher J; Lopez CL; Beutler AS; Loprinzi CL; Vangipuram K; Smith EML; Henry NL; Farris KB; Hertz DL
    Breast; 2020 Jun; 51():21-28. PubMed ID: 32193049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel.
    Reyes-Gibby CC; Morrow PK; Buzdar A; Shete S
    J Pain; 2009 Nov; 10(11):1146-50. PubMed ID: 19595634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer.
    Lee KM; Jung D; Hwang H; Son KL; Kim TY; Im SA; Lee KH; Hahm BJ
    J Psychosom Res; 2018 May; 108():14-19. PubMed ID: 29602320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis.
    Kanbayashi Y; Hosokawa T; Okamoto K; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Taniwaki M
    Anticancer Drugs; 2010 Oct; 21(9):877-81. PubMed ID: 20679888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind, randomized study.
    Park SJ; Yim GW; Paik H; Lee N; Lee S; Lee M; Kim HS
    J Gynecol Oncol; 2021 Sep; 32(5):e73. PubMed ID: 34132071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study.
    Tsurutani J; Sakata Y; Matsuoka T
    Breast Cancer; 2019 Mar; 26(2):235-243. PubMed ID: 30324551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
    Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA
    Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-induced peripheral neuropathy in metastatic breast cancer patients initiating intravenous paclitaxel/nab-paclitaxel.
    Brady BL; Lucci M; Wilson K; Fox KM; Wojtynek J; Cooper C; Varker H; Chebili CL; Dokubo I
    Am J Manag Care; 2021 Jan; 27(1 Spec. No.):SP37-SP43. PubMed ID: 33395243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study.
    Pereira S; Fontes F; Sonin T; Dias T; Fragoso M; Castro-Lopes JM; Lunet N
    Support Care Cancer; 2016 Apr; 24(4):1571-81. PubMed ID: 26384827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.